1.Opportunities for 2-18F Fluoro-2-Deoxy-D-Glucose PET/CT in Cervical-Vaginal Neuroendocrine Carcinoma: Case Series and Literature Review.
Yin LIN ; Wan Y LIN ; Ji A LIANG ; Yu Y LU ; Hsin Y WANG ; Shih C TSAI ; Chia H KAO
Korean Journal of Radiology 2012;13(6):760-770
OBJECTIVE: Neuroendocrine cervical carcinoma is a rare subtype of cervical cancer. These tumors exhibit an aggressive behavior with early regional lymph node and distant metastases. The purpose of our study was to describe five cases of neuroendocrine cervical-vaginal carcinoma and to discuss the potential of the 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan for the detection of this rare malignancy. MATERIALS AND METHODS: Five cases of cervical-vaginal neuroendocrine tumor were retrospectively collected, during a two year (from September 2009 to August 2011) period in our hospital. The clinical staging distributions were International Federation of Gynecology and Obstetrics (FIGO) stage IB2 (1 of 5), stage IIA (3 of 5) and stage IVA (1 of 5). RESULTS: Two cases (cases 1 and 4) were restaged after 18F-FDG PET/CT scan in the initial staging process. Post-treatment 18F-FDG PET/CT scans, in three patients, revealed positive findings for tumor recurrence or lymph node metastases. Two patients (cases 2 and 3) died of tumor within two years. CONCLUSION: 18F-FDG PET/CT scan is a useful tool in cervical-vaginal neuroendocrine tumor. In its initial staging, the 18F-FDG PET/CT scan may help assess the possible nodal involvement or early hematogeneous spreading. We can also use the 18F-FDG PET/CT to detect local recurrence and to evaluate the treatment response after clinical manipulation.
Adult
;
Aged
;
Carcinoma, Neuroendocrine/pathology/*radionuclide imaging/therapy
;
Female
;
Fluorodeoxyglucose F18/*diagnostic use
;
Humans
;
Middle Aged
;
Radiopharmaceuticals/*diagnostic use
;
Uterine Cervical Neoplasms/pathology/*radionuclide imaging/therapy
;
Vaginal Neoplasms/pathology/*radionuclide imaging/therapy
2.Advances in diagnosis and treatment of metastatic cervical cancer.
Haoran LI ; Xiaohua WU ; Xi CHENG
Journal of Gynecologic Oncology 2016;27(4):e43-
Cervical cancer is one of the most common cancers in women worldwide. The outcome of patients with metastatic cervical cancer is poor. We reviewed the relevant literature concerning the treatment and diagnosis of metastatic cervical cancer. There are two types of metastasis related to different treatments and survival rates: hematogenous metastasis and lymphatic metastasis. Patients with hematogenous metastasis have a higher risk of death than those with lymphatic metastasis. In terms of diagnosis, fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) and PET-computed tomography are effective tools for the evaluation of distant metastasis. Concurrent chemoradiotherapy and subsequent chemotherapy are well-tolerated and efficient for lymphatic metastasis. As for lung metastasis, chemotherapy and/or surgery are valuable treatments for resistant, recurrent metastatic cervical cancer and chemoradiotherapy may be the optimal choice for stage IVB cervical cancer. Chemotherapy and bone irradiation are promising for bone metastasis. A better survival is achieved with multimodal therapy. Craniotomy or stereotactic radiosurgery is an optimal choice combined with radiotherapy for solitary brain metastases. Chemotherapy and palliative brain radiation may be considered for multiple brain metastases and other organ metastases.
Bone Neoplasms/secondary/therapy
;
Brain Neoplasms/secondary/therapy
;
Chemoradiotherapy
;
Female
;
Fluorodeoxyglucose F18
;
Humans
;
Lung Neoplasms/secondary/therapy
;
Lymphatic Metastasis
;
Positron-Emission Tomography
;
Uterine Cervical Neoplasms/diagnostic imaging/*pathology/therapy
3.Advances in diagnosis and treatment of metastatic cervical cancer.
Haoran LI ; Xiaohua WU ; Xi CHENG
Journal of Gynecologic Oncology 2016;27(4):e43-
Cervical cancer is one of the most common cancers in women worldwide. The outcome of patients with metastatic cervical cancer is poor. We reviewed the relevant literature concerning the treatment and diagnosis of metastatic cervical cancer. There are two types of metastasis related to different treatments and survival rates: hematogenous metastasis and lymphatic metastasis. Patients with hematogenous metastasis have a higher risk of death than those with lymphatic metastasis. In terms of diagnosis, fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) and PET-computed tomography are effective tools for the evaluation of distant metastasis. Concurrent chemoradiotherapy and subsequent chemotherapy are well-tolerated and efficient for lymphatic metastasis. As for lung metastasis, chemotherapy and/or surgery are valuable treatments for resistant, recurrent metastatic cervical cancer and chemoradiotherapy may be the optimal choice for stage IVB cervical cancer. Chemotherapy and bone irradiation are promising for bone metastasis. A better survival is achieved with multimodal therapy. Craniotomy or stereotactic radiosurgery is an optimal choice combined with radiotherapy for solitary brain metastases. Chemotherapy and palliative brain radiation may be considered for multiple brain metastases and other organ metastases.
Bone Neoplasms/secondary/therapy
;
Brain Neoplasms/secondary/therapy
;
Chemoradiotherapy
;
Female
;
Fluorodeoxyglucose F18
;
Humans
;
Lung Neoplasms/secondary/therapy
;
Lymphatic Metastasis
;
Positron-Emission Tomography
;
Uterine Cervical Neoplasms/diagnostic imaging/*pathology/therapy